Showing 4971-4980 of 5234 results for "".
Are Sunscreens and Cosmetics Really Safe?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/are-sunscreens-and-cosmetics-really-safe/23558/There is basis for some of the concern around skincare ingredients, but dermatologists have the knowledge and expertise to guide patients to products that are safe.Reputation Management for the Modern Dermatology Practice
https://practicaldermatology.com/topics/practice-management/reputation-management-for-the-modern-dermatology-practice/23511/Word-of-mouth marketing has gone online. Here’s what to know.UV Safety Starts Early: We Need to Reach Out to Children
https://practicaldermatology.com/topics/skin-cancer-photoprotection/uv-safety-starts-early-we-need-to-reach-out-to-children/23485/It’s better to instill healthy habits in the young than change behaviors in the old. Here’s how to get started.Stake a Claim: How to Manage Your Online Directory Listings
https://practicaldermatology.com/topics/practice-management/stake-a-claim-how-to-manage-your-online-directory-listings/20350/A simple guide for making sure your listing is accurate.Introducing…the Millennial Patient
https://practicaldermatology.com/topics/practice-management/introducingthe-millennial-patient/20519/Get ready to snap and gram, and prepare to build a lifelong relationship.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sInvasive Melanoma: Incidence, Mortality Continue to Climb
https://practicaldermatology.com/topics/practice-management/invasive-melanoma-incidence-mortality-continue-to-climb/20780/The burden of disease is growing, despite best efforts to combat melanoma.Eyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.Updates on NMSC, Zika, Aesthetics from Summer AAD Meeting
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-updates-on-nmsc-zika-aesthetics-from-summer-aad-meeting/18735/From the dermatologist's role in preparing for Zika to the latest advancements in aesthetics, the Summer meeting of the American Academy of Dermatology in Boston offered fresh insights for practitioners. Get updates on AK Management, the Zika risk, dermatologic care for nursing mothers, fillers, andNoah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.